WARRANT RESTRUCTURING AND ADDITIONAL ISSUANCE AGREEMENTWarrant Restructuring and Additional Issuance Agreement • May 10th, 2019 • Innovation Pharmaceuticals Inc. • Pharmaceutical preparations
This Warrant Restructuring and Additional Issuance Agreement (this “Agreement”), dated as of May 9, 2019, is made pursuant to that certain Securities Purchase Agreement, dated as of October 5, 2018 (the “Purchase Agreement”), as amended, by and between Innovation Pharmaceuticals Inc. (the “Company”) and the purchasers signatory hereto (the “Purchasers”) for the purchase of shares of the Company’s Series B 5% Convertible Preferred Stock (the “Series B Preferred” and such shares, the “Additional Shares”) and Series 4 preferred stock purchase warrants (the “New Warrants”, and together with the Additional Shares, the “Additional Securities”). Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.
